Pierre Fabre files IND application for PFL-002 for solid tumors with MET alterations
June 5, 2024
Pierre Fabre Laboratories (Pierre Fabre SA) has filed an IND application to the FDA to initiate a first-in-human trial with PFL-002 (VERT-002) for solid tumors, including non-small-cell lung cancer (NSCLC).
